中枢神经系统生物标记市场规模、份额、成长分析（按类型、应用、最终用户和地区）- 产业预测，2025 年至 2032 年

2023 年全球中枢神经系统生物标记市场规模为 560 万美元，预计将从 2024 年的 605 万美元增长到 2032 年的 1129 万美元，预测期内（2025-2032 年）的复合年增长率为 8.1%。

受神经系统疾病发病率上升、人口老化和生活方式改变的推动，全球中枢神经系统生物标记市场正在强劲成长。这种快速增长推动了对准确早期诊断的需求，并促进了基于生物标记的工具的整合。技术和研究的进步正在阐明中枢神经系统疾病的分子基础，为具有更高敏感性、特异性和预测能力的创新生物标记铺平了道路。对个人化医疗的关注凸显了生物标记分析对于确定最佳患者群体和追踪治疗反应的重要性。虽然製药业非常重视药物开发和临床试验中的这些生物标誌物，但它面临着诸如解决道德和监管问题以及标准化协议和检验检测的需求等挑战。整体而言，该领域正处于神经病学变革发展的巅峰。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 监管格局
• 专利分析

中枢神经系统生物标记市场规模（按类型和复合年增长率）（2025-2032）

• 市场概况
• 安全生物标记
• 疗效生物标记
• 检验生物标记

中枢神经系统生物标记市场规模（按应用和复合年增长率）（2025-2032）

• 市场概况
• 诊断
  • 阿兹海默症
  • 帕金森氏症
  • 多发性硬化症
  • 中风
• 药物研发
  • 临床前研究
  • 临床试验
• 个人化医疗
  • 基因生物标誌物
  • 蛋白质体生物标记
  • 代谢体学物标誌物

中枢神经系统生物标记市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概况
• 医院
• 诊断实验室
• 研究组织
• 生物製药公司

中枢神经系统生物标记市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• F. Hoffmann-La Roche Ltd（Switzerland）
• Novartis AG（Switzerland）
• Siemens Healthineers AG（Germany）
• Thermo Fisher Scientific Inc.（USA）
• Abbott Laboratories（USA）
• Merck KGaA（Germany）
• Eurofins Scientific（Luxembourg）
• Charles River Laboratories International, Inc.（USA）
• PerkinElmer Inc.（USA）
• Bio-Rad Laboratories, Inc.（USA）
• QIAGEN NV（Netherlands）
• Axon Neuroscience SE（Slovakia）
• Alector Inc.（USA）
• Oryzon Genomics SA（Spain）
• Banyan Biomarkers Inc.（USA）
• Avacta Group PLC（UK）
• Geno Technology Inc.（USA）
• Anavex Life Sciences Corp.（USA）
• Alseres Pharmaceuticals Inc.（USA）
• Aposense Ltd.（Israel）

结论和建议

Global Central Nervous System Biomarkers Market size was valued at USD 5.6 million in 2023 and is poised to grow from USD 6.05 million in 2024 to USD 11.29 million by 2032, growing at a CAGR of 8.1% during the forecast period (2025-2032).

The global CNS biomarker market is witnessing robust growth, propelled by the rising incidence of neurological disorders, an aging population, and evolving lifestyles. This surge is prompting a heightened demand for precise, early diagnostics, fostering the integration of biomarker-based tools. Advances in technology and research are elucidating the molecular foundations of CNS disorders, paving the way for innovative biomarkers that enhance sensitivity, specificity, and predictive power. The focus on personalized medicine emphasizes the importance of biomarker analysis in identifying optimal patient groups and tracking treatment responses. While the pharmaceutical industry values these biomarkers for drug development and clinical trials, the market faces challenges including the need for standardized protocols and validated assays, along with addressing ethical and regulatory concerns. Overall, the sector is set for transformative developments in neurology.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Central Nervous System Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Central Nervous System Biomarkers Market Segmental Analysis

Global Central Nervous System Biomarkers Market is segmented by Type, Application, End-User and region. Based on Type, the market is segmented into Safety Biomarkers, Efficacy Biomarkers and Validation Biomarkers. Based on Application, the market is segmented into Diagnostics, Drug Discovery & Development and Personalized Medicine. Based on End-User, the market is segmented into Hospitals, Diagnostic Laboratories, Research Institutes and Biopharmaceutical Companies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Central Nervous System Biomarkers Market

The global market for Central Nervous System (CNS) biomarkers is significantly driven by the escalating incidence of neurological disorders, including conditions like Alzheimer's disease, Parkinson's disease, and multiple sclerosis. As the prevalence of these ailments continues to rise globally, there is an increasing need for precise and timely diagnostic solutions. This heightened demand emphasizes the importance of biomarker-based diagnostic tools, which are essential for early detection and management of CNS disorders. Consequently, the surge in the number of individuals affected by these conditions propels the growth of the CNS biomarkers market, highlighting the urgent necessity for innovative diagnostic advancements.

Restraints in the Global Central Nervous System Biomarkers Market

One significant restraint in the Global Central Nervous System (CNS) Biomarkers market is the intricate nature of CNS disorders. These conditions are typically characterized by their multifactorial aspects, which complicate the process of pinpointing reliable and specific biomarkers. The diversity and variability within CNS disorders create obstacles in establishing universal biomarkers that can effectively and accurately represent the underlying disease mechanisms. This complexity not only hampers the standardization of biomarker development but also adds to the challenges faced by researchers and healthcare professionals in diagnosing and monitoring CNS diseases, thereby impacting market growth.

Market Trends of the Global Central Nervous System Biomarkers Market

The Global Central Nervous System (CNS) Biomarkers market is experiencing a notable upward trend driven by rapid technological advancements. Innovations like high-throughput screening, next-generation sequencing, and sophisticated imaging techniques significantly enhance the sensitivity and specificity of biomarker detection and analysis. These improvements enable more accurate diagnoses and effective monitoring of CNS disorders, fostering better clinical outcomes. Moreover, as healthcare providers increasingly adopt these technologies, the demand for reliable and precise biomarkers is escalating. This trend is expected to fuel investment in research and development, ultimately positioning CNS biomarkers as a crucial element in personalized medicine and targeted therapies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Central Nervous System Biomarkers Market Size by Type & CAGR (2025-2032)

• Market Overview
• Safety Biomarkers
• Efficacy Biomarkers
• Validation Biomarkers

Global Central Nervous System Biomarkers Market Size by Application & CAGR (2025-2032)

• Market Overview
• Diagnostics
  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Stroke
• Drug Discovery & Development
  • Preclinical Studies
  • Clinical Trials
• Personalized Medicine
  • Genomic Biomarkers
  • Proteomic Biomarkers
  • Metabolomic Biomarkers

Global Central Nervous System Biomarkers Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Diagnostic Laboratories
• Research Institutes
• Biopharmaceutical Companies

Global Central Nervous System Biomarkers Market Size & CAGR (2025-2032)

• North America (Type, Application, End-User)
  • US
  • Canada
• Europe (Type, Application, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories International, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Axon Neuroscience SE (Slovakia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alector Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oryzon Genomics S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Banyan Biomarkers Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Avacta Group PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Geno Technology Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anavex Life Sciences Corp. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alseres Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aposense Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations